Hypertriglyceridemia

Vupanorsen, an investigational antisense therapy, reduced triglyceride levels at 6 months and demonstrated benefit on additional lipid parameters compared with placebo in patients with hypertriglyceridemia, diabetes and hepatic steatosis.

A prespecified analysis of the REDUCE-IT trial highlighted a reduction in first and total revascularization events with icosapent ethyl in patients with elevated triglycerides at high CV risk despite statin therapy.

Future cardiovascular risk among adult patients with depression may be identifiable early using combined data on metabolic syndrome and inflammation, according to results of a population-based cohort study published in JAMA Psychiatry. Researchers used this data to determine that one-third of the association of depression with elevated arterial stiffness index levels during midlife may be accounted for by combined inflammatory and metabolic syndrome processes.

Akcea Therapeutics and Ionis Pharmaceuticals announced that a phase 2 study of AKCEA-ANGPTL3-LRx for the treatment of patients with hypertriglyceridemia, type 2 diabetes and nonalcoholic fatty liver disease met its primary endpoint of significant triglyceride lowering.

One of the top stories in cardiology last week showed that several million Americans with CVD have used marijuana, and experts are warning about the potential health consequences for these high-risk patients.

Akcea Therapeutics and Ionis Pharmaceuticals announced that a phase 2 study of AKCEA-APOCIII-LRx for the treatment of patients with hypertriglyceridemia at risk for or with established CVD met its primary endpoint of significant triglyceride lowering.

The FDA on Friday approved the use of icosapent ethyl as an adjunctive therapy to reduce the risk of cardiovascular events among adults with elevated triglyceride levels, according to an agency press release.

Danish individuals with class II or III obesity are nearly three times more likely to develop acute pancreatitis during 8 years of follow-up compared with adults with normal weight, with the association mediated by hypertriglyceridemia, according to findings published in The Journal of Clinical Endocrinology & Metabolism.

Amarin announced that the Institute for Clinical and Economic Review issued its final report on the cost-effectiveness of icosapent ethyl and found that the medication has “high long-term value for money.”

CHICAGO — Findings of cardiovascular benefit with icosapent ethyl treatment from the REDUCE-IT trial have already revealed actionable clinical implications, but determining whether triglyceride reductions or eicosapentaenoic acid increases are the key mechanisms will be the focus of continuing research, according to a speaker at the Cardiometabolic Heath Congress.